ArticleCadernos de saude publica2026
Dipyrone use in Brazil: clinical conditions, sociodemographic characteristics, population attitudes and perceptions.
Article in Cadernos de saude publica, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Maternal Dipyrone Exposure and Risk of Major Congenital Malformations, Adverse Perinatal and Postnatal Outcomes: A Population-Based Cohort Study.Clinical pharmacology and therapeutics · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study aims to analyze self-reported dipyrone use among the Brazilian population. We used data from the Brazilian National Survey on Access, Use, and Promotion of Rational Use of Medicines (PNAUM), conducted from September 2013 to February 2014 in urban areas of five regions of Brazil. The study population included individuals of all ages, with a minimum sample size of 960 interviews per sample domain, totaling 41,433 respondents and representing approximately 17 million Brazilians. We assessed socioeconomic and demographic characteristics, profiles of chronic and acute diseases, medication use, health perceptions, and perceived effectiveness and safety of dipyrone - either alone or in combination with other medications. The Poisson regression model was used to estimate adjusted prevalence ratios (aPR). The results showed that 10.4% of respondents reported using dipyrone, with 98.3% of these users taking it for acute conditions, such as pain (77.9%) and fever (14.5%). After adjusting for variables, dipyrone use for pain was more common among women (aPR = 1.66; 95%CI: 1.47-1.88) and among individuals living in the Central-West (aPR = 1.32; 95%CI: 1.04-1.67), particularly those with chronic conditions or acute events. Use for fever was similar between genders but more common among children aged under 10 years (PR = 0.62; 95%CI: 0.46-0.82). Half of the users combined dipyrone with other medications, and this practice was ten times more frequent for pain than for fever. Lastly, the effectiveness of dipyrone was widely perceived as positive, with few reports of adverse effects.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.